{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032328","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.979209+00:00","generated_at":"2026-05-31T09:26:12.458750+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M","bullets":["Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.","Net loss improved to $257K from $9.8M; adjusted EBITDA -$4.7M vs -$7.9M in prior year.","Cash and equivalents $4.4M at June 30, 2024, up from $1.3M at Dec 31, 2023; raised $8.0M from May 2024 warrant exercises.","Launched FDA-approved RhodoLED XL lamp in June; shipped first three machines within one week of launch.","Took control of all US clinical trials for Ameluz on June 1, 2024, under amended license agreement to reduce costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032328","json":"https://secwatch.observer/filing/0001493152-24-032328.json","markdown":"https://secwatch.observer/filing/0001493152-24-032328.md","text":"https://secwatch.observer/filing/0001493152-24-032328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/0001493152-24-032328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224032328/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:26:12.458750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}